NCT03297385View on ClinicalTrials.gov

Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 28, 2014

Primary Completion Date

April 1, 2017

Study Completion Date

April 1, 2017

Conditions

Prostate CancerDNAAndrogen Receptor Abnormal

Interventions

DRUG

Enzalutamide

Men with localized prostate cancer will undergo an additional set of targeted tumor biopsies and will be subsequently treated with 3 months of enzalutamide. The prostatectomy specimen will be additionally sampled, ex vivo.